Rochelle Lewis advocates for renaming Polycystic Ovary Syndrome (PCOS) to better reflect the condition's complex reality and improve diagnosis rates among women worldwide. The condition affects over 170 million women globally, yet remains chronically underdiagnosed and misunderstood.
Lewis argues that the current name misleads patients and clinicians alike. PCOS doesn't always present with cysts on the ovaries, and naming the condition after this single visual marker obscures its systemic nature. The disorder involves hormonal imbalances, metabolic dysfunction, and reproductive challenges that extend far beyond ovarian morphology. This naming confusion delays diagnosis, leaving women unaware they have the condition and unable to access proper treatment.
The push for renaming gains traction as medical communities recognize PCOS as a metabolic and endocrine disorder, not merely a reproductive one. Women often struggle for years with unexplained weight gain, irregular periods, excess hair growth, and infertility before receiving a diagnosis. By the time doctors identify PCOS, preventable complications like type 2 diabetes have sometimes already developed.
Advocates propose alternatives like "Metabolic Reproductive Syndrome" or simply "Ovulatory Dysfunction Disorder" that better capture the condition's scope. Renaming carries real stakes. A clearer name would help women recognize symptoms earlier, prompt faster clinical identification, and facilitate more inclusive screening protocols.
Beyond nomenclature, renaming PCOS signals validation for millions of women whose suffering goes unrecognized under the current terminology. It acknowledges that their experiences extend beyond textbook definitions tied to ultrasound findings. Medical language shapes clinical practice and patient understanding. Getting the name right means getting the diagnosis right, and ultimately, getting women the care they deserve.